Making 3D cell-based technologies accessible and actionable – remaining challenges and potential solutions
3D cell-based technologies such as spheroids, organoids, 3D bioprinting and organ-on-chip have made significant progress in the last years. However, unlocking the potential of these technologies in pharmaceutical R&D and clinics proves more complex than expected. Reliable cell sources, reproducible production and standardization, continuous supply chain, sufficient throughput and ease of use at, finally, reasonable cost are some of the challenges faced. Innovations are bein
Olivier Frey, Vice President – Technologies & Platforms, InSphero
- Nikolche Gjorevski, Principal Scientist and Lead, Roche Institute for Translational Bioengineering
- Salvatore Piscuoglio, Research Group Leader, University of Basel
- Stéphanie Boder-Pache, Project Manager, CSEM
- Gabriel Liguori, CEO, TissueLabs
CSEM is an applied research and development organization with sites in Neuchâtel, Alpnach, Basel, Landquart, Zürich and Bern. We develop and transfer technologies to create sustainable economic value for the Swiss industrial sector. Our three technology platforms (digital technologies, precision manufacturing and sustainable energy) impact several industrial sectors, including biotech where CSEM develops innovative tools and platforms to enable a more personalized healthcare.